Cargando…
A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy
PURPOSE: To assess the relative cost-effectiveness of cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy (DCM) compared with periodical clinical surveillance. METHODS: A decision-analytic model, combining a decision tree and a Markov model, was used to determin...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group US
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892743/ https://www.ncbi.nlm.nih.gov/pubmed/31222143 http://dx.doi.org/10.1038/s41436-019-0582-2 |
_version_ | 1783476069573066752 |
---|---|
author | Catchpool, Max Ramchand, Jay Martyn, Melissa Hare, David L. James, Paul A. Trainer, Alison H. Knight, Josh Goranitis, Ilias |
author_facet | Catchpool, Max Ramchand, Jay Martyn, Melissa Hare, David L. James, Paul A. Trainer, Alison H. Knight, Josh Goranitis, Ilias |
author_sort | Catchpool, Max |
collection | PubMed |
description | PURPOSE: To assess the relative cost-effectiveness of cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy (DCM) compared with periodical clinical surveillance. METHODS: A decision-analytic model, combining a decision tree and a Markov model, was used to determine the lifetime costs and quality-adjusted life years (QALYs) for the two strategies. Deterministic and probabilistic sensitivity analyses were undertaken to assess the robustness of findings and to explore decision uncertainty. RESULTS: The incremental cost per additional QALY of cascade genetic testing prior to periodical clinical surveillance of first-degree relatives compared with periodical clinical surveillance alone was estimated at approximately AUD $6100. At established thresholds of cost-effectiveness, there is a 90% probability that cascade genetic testing is cost-effective. Extensive sensitivity analyses, including the addition of second-degree relatives, did not alter the conclusions drawn from the main analysis. CONCLUSION: Using cascade genetic testing to guide clinical surveillance of asymptomatic relatives of patients with DCM is very likely to be cost-effective. As the DCM pathogenic variant detection rate rises and new evidence for personalized treatment of at-risk individuals becomes available, the cost-effectiveness of cascade testing will further increase. |
format | Online Article Text |
id | pubmed-6892743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Nature Publishing Group US |
record_format | MEDLINE/PubMed |
spelling | pubmed-68927432019-12-06 A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy Catchpool, Max Ramchand, Jay Martyn, Melissa Hare, David L. James, Paul A. Trainer, Alison H. Knight, Josh Goranitis, Ilias Genet Med Article PURPOSE: To assess the relative cost-effectiveness of cascade genetic testing in asymptomatic relatives of patients with dilated cardiomyopathy (DCM) compared with periodical clinical surveillance. METHODS: A decision-analytic model, combining a decision tree and a Markov model, was used to determine the lifetime costs and quality-adjusted life years (QALYs) for the two strategies. Deterministic and probabilistic sensitivity analyses were undertaken to assess the robustness of findings and to explore decision uncertainty. RESULTS: The incremental cost per additional QALY of cascade genetic testing prior to periodical clinical surveillance of first-degree relatives compared with periodical clinical surveillance alone was estimated at approximately AUD $6100. At established thresholds of cost-effectiveness, there is a 90% probability that cascade genetic testing is cost-effective. Extensive sensitivity analyses, including the addition of second-degree relatives, did not alter the conclusions drawn from the main analysis. CONCLUSION: Using cascade genetic testing to guide clinical surveillance of asymptomatic relatives of patients with DCM is very likely to be cost-effective. As the DCM pathogenic variant detection rate rises and new evidence for personalized treatment of at-risk individuals becomes available, the cost-effectiveness of cascade testing will further increase. Nature Publishing Group US 2019-06-20 2019 /pmc/articles/PMC6892743/ /pubmed/31222143 http://dx.doi.org/10.1038/s41436-019-0582-2 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
spellingShingle | Article Catchpool, Max Ramchand, Jay Martyn, Melissa Hare, David L. James, Paul A. Trainer, Alison H. Knight, Josh Goranitis, Ilias A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy |
title | A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy |
title_full | A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy |
title_fullStr | A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy |
title_full_unstemmed | A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy |
title_short | A cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy |
title_sort | cost-effectiveness model of genetic testing and periodical clinical screening for the evaluation of families with dilated cardiomyopathy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892743/ https://www.ncbi.nlm.nih.gov/pubmed/31222143 http://dx.doi.org/10.1038/s41436-019-0582-2 |
work_keys_str_mv | AT catchpoolmax acosteffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT ramchandjay acosteffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT martynmelissa acosteffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT haredavidl acosteffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT jamespaula acosteffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT traineralisonh acosteffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT knightjosh acosteffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT goranitisilias acosteffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT catchpoolmax costeffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT ramchandjay costeffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT martynmelissa costeffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT haredavidl costeffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT jamespaula costeffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT traineralisonh costeffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT knightjosh costeffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy AT goranitisilias costeffectivenessmodelofgenetictestingandperiodicalclinicalscreeningfortheevaluationoffamilieswithdilatedcardiomyopathy |